leisure time -WSS

leisure time

author：entertainment 2025-08-24 10:14:32 - browse：64

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： The Bio Revolution is changing business and society

knowledge

WSS

The drug industry has found itself all alone in Washington

Beyond aggravation: Constipation is an American epidemic

Beyond aggravation: Constipation is an American epidemic

Should insurance cover cosmetic surgery?

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

IVF, abortion rights issues kick off Biden’s State of the Union

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

New research sheds light on how often breast cancer is overdiagnosed

Virginia high school admissions case could be legal follow

Change Healthcare payments predicted restored March 15

The cancer drug shortage isn’t new — and neither are the solutions

Headspace, Meta partner to launch VR meditation app for Quest

Affirmative action in medical school literally saved lives

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

hotspot

Novo Nordisk obesity pill bests Wegovy in early trial

NEJM study link tiny plastics in blood vessels to heart problems

Just how do doctors, lawmakers, and the public define abortion?

The drug industry has found itself all alone in Washington

Stroke rates rising, especially in working

Pharma’s losing bet in New Jersey

hotspot

hotspot

knowledge

knowledge